Search

Your search keyword '"Kuipers, Maria T."' showing total 31 results
Start Over Author "Kuipers, Maria T." Search Limiters Available in Library Collection
31 results on '"Kuipers, Maria T."'

1. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Author

Frerichs, Kristine A., Verkleij, Christie P. M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, van der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., and van de Donk, Niels W. C. J.

Published
2024
Full Text
View/download PDF

2. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma:importance of immunoglobulin supplementation

Author

Frerichs, Kristine A., Verkleij, Christie P.M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Van Der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., Van De Donk, Niels W.C.J., Frerichs, Kristine A., Verkleij, Christie P.M., Mateos, Maria Victoria, Martin, Thomas G., Rodriguez, Cesar, Nooka, Ajay, Banerjee, Arnob, Chastain, Katherine, Perales-Puchalt, Alfredo, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Van Der Holt, Bronno, Kruyswijk, Sandy, Kuipers, Maria T., Groen, Kaz, Vishwamitra, Deeksha, Skerget, Sheri, Cortes-Selva, Diana, Doyle, Margaret, Zaaijer, Hans L., Zweegman, Sonja, Verona, Raluca I., and Van De Donk, Niels W.C.J.

Abstract

Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received onceweekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P < .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098.

Published
2024

3. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data

Author

Onderzoeksgroep Minnema, Researchteam, MS Hematologie, Cancer, Centraal Diagnostisch Laboratorium, Other research (not in main researchprogram), CTI Kuball, Infection & Immunity, Regenerative Medicine and Stem Cells, CTI De Witte, Weverling, Flores Gerrit, Roeven, Mieke W H, Nijssen, Klaartje Kasper, Broers, Annoek E C, Dovern, Elisabeth, van Rhenen, Anna, Sluis, Geerte van, Hazenberg, Carin, van Balen, Peter, Kuipers, Maria T, de Vooght, Karen M K, Morsink, Linde M, Kuball, Jürgen, Nur, Erfan, Dewitte, Moniek, Onderzoeksgroep Minnema, Researchteam, MS Hematologie, Cancer, Centraal Diagnostisch Laboratorium, Other research (not in main researchprogram), CTI Kuball, Infection & Immunity, Regenerative Medicine and Stem Cells, CTI De Witte, Weverling, Flores Gerrit, Roeven, Mieke W H, Nijssen, Klaartje Kasper, Broers, Annoek E C, Dovern, Elisabeth, van Rhenen, Anna, Sluis, Geerte van, Hazenberg, Carin, van Balen, Peter, Kuipers, Maria T, de Vooght, Karen M K, Morsink, Linde M, Kuball, Jürgen, Nur, Erfan, and Dewitte, Moniek

Published
2024

4. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation:Dutch real-world data

Author

Weverling, Flores, Roeven, Mieke, Nijssen, Clara, Broers, Annoek E.C., Dovern, Elisabeth, Van Rhenen, Anna, Van Sluis, Geerte, Hazenberg, Carin L.E., Van Balen, Peter, Kuipers, Maria T., De Vooght, Karen M.K., Morsink, Linde, Kuball, Jürgen, Nur, Erfan, De Witte, Moniek A., Weverling, Flores, Roeven, Mieke, Nijssen, Clara, Broers, Annoek E.C., Dovern, Elisabeth, Van Rhenen, Anna, Van Sluis, Geerte, Hazenberg, Carin L.E., Van Balen, Peter, Kuipers, Maria T., De Vooght, Karen M.K., Morsink, Linde, Kuball, Jürgen, Nur, Erfan, and De Witte, Moniek A.

Published
2024

6. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data

Author

Weverling, Flores Gerrit, primary, Roeven, Mieke W.H., additional, Nijssen, Klaartje Kasper, additional, Broers, Annoek E.C., additional, Dovern, Elisabeth, additional, van Rhenen, Anna, additional, Sluis, Geerte van, additional, Hazenberg, Carin, additional, van Balen, Peter, additional, Kuipers, Maria T, additional, de Vooght, Karen M.K., additional, Morsink, Linde M., additional, Kuball, Jürgen, additional, Nur, Erfan, additional, and Dewitte, Moniek, additional

Published
2024
Full Text
View/download PDF

7. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

Author

de Boer, Janneke W., primary, Pennings, Elise R. A., additional, Kleinjan, Ankie, additional, van Doesum, Jaap A., additional, Spanjaart, Anne M., additional, Mutsaers, Pim G. N. J., additional, Jak, Margot, additional, van der Poel, Marjolein W. M., additional, Kuipers, Maria T., additional, Adam, Judit A., additional, Diepstra, Arjan, additional, Koens, Lianne, additional, van Dorp, Suzanne, additional, Vermaat, Joost S. P., additional, Niezink, Anne G. H., additional, Kersten, Marie José, additional, and van Meerten, Tom, additional

Published
2023
Full Text
View/download PDF

8. The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., primary, Pennings, Elise R. A., additional, Mutsaers, Pim G. N. J., additional, van Dorp, Suzanne, additional, Jak, Margot, additional, van Doesum, Jaap A., additional, de Boer, Janneke W., additional, Niezink, Anne G. H., additional, Kos, Milan, additional, Vermaat, Joost S. P., additional, Sijs-Szabo, Aniko, additional, van der Poel, Marjolein W. M., additional, Nijhof, Inger S., additional, Kuipers, Maria T., additional, Chamuleau, Martine E. D., additional, Lugtenburg, Pieternella J., additional, Doorduijn, Jeanette K., additional, Serroukh, Yasmina I. M., additional, Minnema, Monique C., additional, van Meerten, Tom, additional, and Kersten, Marie José, additional

Published
2023
Full Text
View/download PDF

9. P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY

Author

Pennings, Elise R.A., primary, Durmaz, Müjde, additional, Visser, Otto, additional, Posthuma, Eduardus F.M., additional, Issa, Djamila E., additional, Chamuleau, Martine E.D., additional, Spanjaart, Anne M., additional, van Meerten, Tom, additional, Mutsaers, Pim G.N.J., additional, Jak, Margot, additional, van Dorp, Suzanne, additional, Vermaat, Joost S.P., additional, van der Poel, Marjolein W.M., additional, Kuipers, Maria T., additional, Thielen, Frederick W., additional, Uyl-de Groot, Carin A., additional, Lugtenburg, Pieternella J., additional, José Kersten, Marie, additional, and Dinmohamed, Avinash G., additional

Published
2023
Full Text
View/download PDF

10. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

Author

Apotheek Klinische Farmacie Kinderen, Apotheek Onderzoek, Huntjens, Daan W., Dijkstra, Jacob A., Verwiel, Lisanne N., Slijkhuis, Mirjam, Elbers, Paul, Welkers, Matthijs R.A., Veldkamp, Agnes I., Kuijvenhoven, Marianne A., de Leeuw, David C., Abdullah-Koolmees, Heshu, Kuipers, Maria T., Bartelink, Imke H., Apotheek Klinische Farmacie Kinderen, Apotheek Onderzoek, Huntjens, Daan W., Dijkstra, Jacob A., Verwiel, Lisanne N., Slijkhuis, Mirjam, Elbers, Paul, Welkers, Matthijs R.A., Veldkamp, Agnes I., Kuijvenhoven, Marianne A., de Leeuw, David C., Abdullah-Koolmees, Heshu, Kuipers, Maria T., and Bartelink, Imke H.

Published
2023

11. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

Author

de Boer, Janneke W., Pennings, Elise R.A., Kleinjan, Ankie, van Doesum, Jaap A., Spanjaart, Anne M., Mutsaers, Pim G.N.J., Jak, Margot, van der Poel, Marjolein W.M., Kuipers, Maria T., Adam, Judit A., Diepstra, Arjan, Koens, Lianne, van Dorp, Suzanne, Vermaat, Joost S.P., Niezink, Anne G.H., Kersten, Marie José, van Meerten, Tom, de Boer, Janneke W., Pennings, Elise R.A., Kleinjan, Ankie, van Doesum, Jaap A., Spanjaart, Anne M., Mutsaers, Pim G.N.J., Jak, Margot, van der Poel, Marjolein W.M., Kuipers, Maria T., Adam, Judit A., Diepstra, Arjan, Koens, Lianne, van Dorp, Suzanne, Vermaat, Joost S.P., Niezink, Anne G.H., Kersten, Marie José, and van Meerten, Tom

Published
2023

12. The Dutch CAR-T Tumorboard Experience:Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Author

Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, Kersten, Marie José, Spanjaart, Anne M., Pennings, Elise R.A., Mutsaers, Pim G.N.J., van Dorp, Suzanne, Jak, Margot, van Doesum, Jaap A., de Boer, Janneke W., Niezink, Anne G.H., Kos, Milan, Vermaat, Joost S.P., Sijs-Szabo, Aniko, van der Poel, Marjolein W.M., Nijhof, Inger S., Kuipers, Maria T., Chamuleau, Martine E.D., Lugtenburg, Pieternella J., Doorduijn, Jeanette K., Serroukh, Yasmina I.M., Minnema, Monique C., van Meerten, Tom, and Kersten, Marie José

Abstract

The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need.

Published
2023

13. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Author

Spanjaart, Anne M., Pennings, Elise R.A., Kos, Milan, Mutsaers, Pim G.N.J., Lugtenburg, Pieternella J., Van Meerten, Tom, Van Doesum, Jaap A., Minnema, Monique C., Jak, Margot, Van Dorp, Suzanne, Vermaat, Joost S.P., Van Der Poel, Marjolein W.M., Van Oijen, Martijn G.H., Kuipers, Maria T., Nijhof, Inger S., Kersten, Marie José, Spanjaart, Anne M., Pennings, Elise R.A., Kos, Milan, Mutsaers, Pim G.N.J., Lugtenburg, Pieternella J., Van Meerten, Tom, Van Doesum, Jaap A., Minnema, Monique C., Jak, Margot, Van Dorp, Suzanne, Vermaat, Joost S.P., Van Der Poel, Marjolein W.M., Van Oijen, Martijn G.H., Kuipers, Maria T., Nijhof, Inger S., and Kersten, Marie José

Abstract

PURPOSE:Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell-mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs and symptoms marking these acute toxicities. This study provides a core set of patient- and caregiver-reported signs and symptoms (outcomes, P/CROs) and definitions of red flags warranting immediate action to include in a daily checklist for support at home, with the goal to make outpatient post-CAR T-cell care safer, optimize patient and caregiver support, and thereby facilitating an early discharge/hospital visit reduction strategy.METHODS:We performed a systematic review of phase II/III trials of US Food and Drug Administration-approved CAR T-cell products and selected all common and severe adverse events that could be translated into a P/CRO for inclusion in a two-round modified Delphi procedure. Eleven CAR T-cell-dedicated hematologists from the Dutch CAR T-cell tumorboard representing all treating centers selected P/CROs for inclusion in the core set and defined red flags. The final core set was evaluated with patients and caregivers.RESULTS:From nine clinical trials, 457 adverse events were identified of which 42 could be used as P/CRO. The final core set contains 28 items, including five signs for measurement via wearables and two signs for caregiver-performed assessments.CONCLUSION:This study provides a core set of P/CROs that can serve as a framework for (eHealth) tools that aim to enable patients and caregivers to more effectively recognize and report signs and symptoms of acute toxicities after CAR T-cell therapy, which will enhance safe outpatient treatment monitoring.

Published
2023

14. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

Author

MS Hematologie, Cancer, Infection & Immunity, de Boer, Janneke W., Pennings, Elise R.A., Kleinjan, Ankie, van Doesum, Jaap A., Spanjaart, Anne M., Mutsaers, Pim G.N.J., Jak, Margot, van der Poel, Marjolein W.M., Kuipers, Maria T., Adam, Judit A., Diepstra, Arjan, Koens, Lianne, van Dorp, Suzanne, Vermaat, Joost S.P., Niezink, Anne G.H., Kersten, Marie José, van Meerten, Tom, MS Hematologie, Cancer, Infection & Immunity, de Boer, Janneke W., Pennings, Elise R.A., Kleinjan, Ankie, van Doesum, Jaap A., Spanjaart, Anne M., Mutsaers, Pim G.N.J., Jak, Margot, van der Poel, Marjolein W.M., Kuipers, Maria T., Adam, Judit A., Diepstra, Arjan, Koens, Lianne, van Dorp, Suzanne, Vermaat, Joost S.P., Niezink, Anne G.H., Kersten, Marie José, and van Meerten, Tom

Published
2023

15. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Externen Med. Onco, Spanjaart, Anne M, Pennings, Elise R A, Kos, Milan, Mutsaers, Pim G N J, Lugtenburg, Pieternella J, van Meerten, Tom, van Doesum, Jaap A, Minnema, Monique C, Jak, Margot, van Dorp, Suzanne, Vermaat, Joost S P, van der Poel, Marjolein W M, van Oijen, Martijn G H, Kuipers, Maria T, Nijhof, Inger S, Kersten, Marie José, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Externen Med. Onco, Spanjaart, Anne M, Pennings, Elise R A, Kos, Milan, Mutsaers, Pim G N J, Lugtenburg, Pieternella J, van Meerten, Tom, van Doesum, Jaap A, Minnema, Monique C, Jak, Margot, van Dorp, Suzanne, Vermaat, Joost S P, van der Poel, Marjolein W M, van Oijen, Martijn G H, Kuipers, Maria T, Nijhof, Inger S, and Kersten, Marie José

Published
2023

16. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

Author

Huntjens, Daan W., primary, Dijkstra, Jacob A., additional, Verwiel, Lisanne N., additional, Slijkhuis, Mirjam, additional, Elbers, Paul, additional, Welkers, Matthijs R. A., additional, Veldkamp, Agnes I., additional, Kuijvenhoven, Marianne A., additional, de Leeuw, David C., additional, Abdullah-Koolmees, Heshu, additional, Kuipers, Maria T., additional, and Bartelink, Imke H., additional

Published
2023
Full Text
View/download PDF

23. High Levels of S100A8/A9 Proteins Aggravate Ventilator-Induced Lung Injury via TLR4 Signaling

Author

Kuipers, Maria T., primary, Vogl, Thomas, additional, Aslami, Hamid, additional, Jongsma, Geartsje, additional, van den Berg, Elske, additional, Vlaar, Alexander P. J., additional, Roelofs, Joris J. T. H., additional, Juffermans, Nicole P., additional, Schultz, Marcus J., additional, van der Poll, Tom, additional, Roth, Johannes, additional, and Wieland, Catharina W., additional

Published
2013
Full Text
View/download PDF

24. Hydrogen Sulfide Donor NaHS Reduces Organ Injury in a Rat Model of Pneumococcal Pneumosepsis, Associated with Improved Bio-Energetic Status

Author

Aslami, Hamid, primary, Pulskens, Wilco P., additional, Kuipers, Maria T., additional, Bos, Aafkeline P., additional, van Kuilenburg, André B. P., additional, Wanders, Ronald J. A., additional, Roelofsen, Jeroen, additional, Roelofs, Joris J. T. H., additional, Kerindongo, Raphaela P., additional, Beurskens, Charlotte J. P., additional, Schultz, Marcus J., additional, Kulik, Wim, additional, Weber, Nina C., additional, and Juffermans, Nicole P., additional

Published
2013
Full Text
View/download PDF

26. Pre-Treatment with Allopurinol or Uricase Attenuates Barrier Dysfunction but Not Inflammation during Murine Ventilator-Induced Lung Injury

Author

Kuipers, Maria T., primary, Aslami, Hamid, additional, Vlaar, Alexander P. J., additional, Juffermans, Nicole P., additional, Tuip-de Boer, Anita M., additional, Hegeman, Maria A., additional, Jongsma, Geartsje, additional, Roelofs, Joris J. T. H., additional, van der Poll, Tom, additional, Schultz, Marcus J., additional, and Wieland, Catharina W., additional

Published
2012
Full Text
View/download PDF

29. Ventilator-induced Lung Injury Is Mediated by the NLRP3 Inflammasome

Author

Kuipers, Maria T., primary, Aslami, Hamid, additional, Janczy, John R., additional, van der Sluijs, Koenraad F., additional, Vlaar, Alexander P. J., additional, Wolthuis, Esther K., additional, Choi, Goda, additional, Roelofs, Joris J. T. H., additional, Flavell, Richard A., additional, Sutterwala, Fayyaz S., additional, Bresser, Paul, additional, Leemans, Jaklien C., additional, van der Poll, Tom, additional, Schultz, Marcus J., additional, and Wieland, Catharina W., additional

Published
2012
Full Text
View/download PDF

31. The caspase inhibitor zVAD increases lung inflammation in pneumovirus infection in mice.

Author

Berg, Elske, Bal, Suzanne M., Kuipers, Maria T., Matute‐Bello, Gustavo, Lutter, René, Bos, Albert P., Woensel, Job B. M., and Bem, Reinout A.

Subjects
ADULT respiratory distress syndrome, APOPTOSIS, NEUTROPHILS, RESPIRATORY syncytial virus, CASPASE inhibitors, LABORATORY mice
Abstract

Severe respiratory syncytial virus ( RSV) disease is a frequent cause of acute respiratory distress syndrome ( ARDS) in young children, and is associated with marked lung epithelial injury and neutrophilic inflammation. Experimental studies on ARDS have shown that inhibition of apoptosis in the lungs reduces lung epithelial injury. However, the blockade of apoptosis in the lungs may also have deleterious effects by hampering viral clearance, and importantly, by enhancing or prolonging local proinflammatory responses. The aim of this study was to determine the effect of the broad caspase inhibitor Z- VAD( OMe)- FMK ( zVAD) on inflammation and lung injury in a mouse pneumovirus model for severe RSV disease. Eight- to 11-week-old female C57 BL/6OlaHsd mice were inoculated with the rodent-specific pneumovirus pneumonia virus of mice ( PVM) strain J3666 and received multiple injections of zVAD or vehicle (control) during the course of disease, after which they were studied for markers of apoptosis, inflammation, and lung injury on day 7 after infection. PVM-infected mice that received zVAD had a strong increase in neutrophil numbers in the lungs, which was associated with decreased neutrophil apoptosis. Furthermore, zVAD treatment led to higher concentrations of several proinflammatory cytokines in the lungs and more weight loss in PVM-infected mice. In contrast, zVAD did not reduce apoptosis of lung epithelial cells and did not affect the degree of lung injury, permeability, and viral titers in PVM disease. We conclude that zVAD has an adverse effect in severe pneumovirus disease in mice by enhancing the lung proinflammatory response. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results